Abstract
Background: This study was designed to evaluate the value of plasma cystatin C in predicting adverse cardiac events after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). Methods: A total of 605 patients (404 male, mean age 60.4 ± 10.6 years) with ACS underwent successful PCI. Patients were divided into 4 groups according to the level of cystatin C, which was measured before the PCI: Q1 (<1.02 mg/L), Q2 (1.02-1.16 mg/L), Q3 (1.17-1.34 mg/L), and Q4 (≥1.35 mg/L). Results: After a follow-up of 14.3 ± 1.7 months, the incidence of mortality, nonfatal myocardial infarction, and target lesion revascularization in the Q2, Q3, and Q4 groups was higher than in the Q1 group (P < .001). The incidence of heart failure in the Q3 and Q4 groups was higher than in the Q1 group (P < .05). Multivariate Cox regression analysis showed that cystatin C elevation was an independent predictor of major adverse cardiac events. The cumulative survival rate of the Q3 and Q4 groups was lower than in the Q1 group (P < .001). Conclusion: High plasma cystatin C concentration is an independent predictor of major adverse cardiac events in patients with ACS treated with PCI.
Original language | English (US) |
---|---|
Pages (from-to) | 456-462 |
Number of pages | 7 |
Journal | Heart and Lung: Journal of Acute and Critical Care |
Volume | 41 |
Issue number | 5 |
DOIs | |
State | Published - Sep 2012 |
Externally published | Yes |
Keywords
- Acute coronary syndrome
- Cystatin C
- Major adverse cardiac events
- Percutaneous coronary intervention
- Prognosis
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Critical Care and Intensive Care Medicine
- Cardiology and Cardiovascular Medicine